DE602005027307D1 - Arylanilinderivate als agonisten des beta2-adrenergen rezeptors - Google Patents

Arylanilinderivate als agonisten des beta2-adrenergen rezeptors

Info

Publication number
DE602005027307D1
DE602005027307D1 DE602005027307T DE602005027307T DE602005027307D1 DE 602005027307 D1 DE602005027307 D1 DE 602005027307D1 DE 602005027307 T DE602005027307 T DE 602005027307T DE 602005027307 T DE602005027307 T DE 602005027307T DE 602005027307 D1 DE602005027307 D1 DE 602005027307D1
Authority
DE
Germany
Prior art keywords
adreneer
arylaniline
beta2
agonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005027307T
Other languages
English (en)
Inventor
Robert Murray Mckinnell
John R Jacobsen
Sean G Trapp
Daisuke Roland Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of DE602005027307D1 publication Critical patent/DE602005027307D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
DE602005027307T 2004-01-12 2005-01-11 Arylanilinderivate als agonisten des beta2-adrenergen rezeptors Active DE602005027307D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53578404P 2004-01-12 2004-01-12
PCT/US2005/000810 WO2005070872A1 (en) 2004-01-12 2005-01-11 Aryl aniline derivatives as beta2 adrenergic receptor agonists

Publications (1)

Publication Number Publication Date
DE602005027307D1 true DE602005027307D1 (de) 2011-05-19

Family

ID=34806964

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005027307T Active DE602005027307D1 (de) 2004-01-12 2005-01-11 Arylanilinderivate als agonisten des beta2-adrenergen rezeptors

Country Status (19)

Country Link
US (3) US7622467B2 (de)
EP (1) EP1706371B1 (de)
JP (1) JP5041814B2 (de)
CN (1) CN1910137B (de)
AR (1) AR047098A1 (de)
AT (1) ATE504559T1 (de)
AU (1) AU2005206510A1 (de)
BR (1) BRPI0506823A (de)
CA (1) CA2551821A1 (de)
DE (1) DE602005027307D1 (de)
ES (1) ES2364450T3 (de)
IL (1) IL176549A0 (de)
MA (1) MA28304A1 (de)
NO (1) NO20063620L (de)
NZ (1) NZ548196A (de)
RU (1) RU2370490C2 (de)
TW (1) TW200531692A (de)
WO (1) WO2005070872A1 (de)
ZA (1) ZA200605720B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200134B1 (en) 1998-01-20 2001-03-13 Kerr Corporation Apparatus and method for curing materials with radiation
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US7182597B2 (en) 2002-08-08 2007-02-27 Kerr Corporation Curing light instrument
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
CN1984876A (zh) * 2004-06-03 2007-06-20 施万制药 二胺类β2肾上腺素能受体激动剂
EP1778638A1 (de) * 2004-07-21 2007-05-02 Theravance, Inc. Adrenergische diaryl ether beta2-rezeptoragonisten
JP2008512470A (ja) * 2004-09-10 2008-04-24 セラヴァンス， インコーポレーテッド アミジン置換アリールアニリン化合物
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
BRPI0606712A2 (pt) * 2005-01-11 2010-03-16 Glaxo Group Ltd sal do composto, formulação farmacêutica, combinação, uso de um composto, e, método para preparar um composto cristalino
ES2265276B1 (es) * 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US8113830B2 (en) 2005-05-27 2012-02-14 Kerr Corporation Curing light instrument
EP2281813A1 (de) 2005-08-08 2011-02-09 Pulmagen Therapeutics (Synergy) Limited Bicyclo[2.2.1]Hept-7-Ylamin Derivate und deren Verwendung
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200745067A (en) * 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
EP2322525B1 (de) 2006-04-21 2013-09-18 Novartis AG Purinderivate als Adenosin A2A Rezeptoragonisten
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (de) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. 4-(2-Amino-1-hydroxyethyl)Phenol-Derivate als Agonisten des b2-adrenergen Rezeptors
TW201002696A (en) 2008-06-18 2010-01-16 Astrazeneca Ab Novel compounds 409
US8236786B2 (en) * 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
CA2748331C (en) 2008-12-30 2016-08-02 Pulmagen Therapeutics (Inflammation) Limited Sulfonamide compounds for the treatment of respiratory disorders
EP2228368A1 (de) 2009-03-12 2010-09-15 Almirall, S.A. Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
GEP20156285B (en) 2011-02-25 2015-05-11 Aierem Elelsi Compounds and compositions as trk inhibitors
EP2578570A1 (de) 2011-10-07 2013-04-10 Almirall, S.A. Neues Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxychinolin-2(1H)-on mittels neuen Synthesezwischenstoffen
EP2641900A1 (de) 2012-03-20 2013-09-25 Almirall, S.A. Neuartige polymorphe Kristallformen von 5-(2-{[6-(2,2-difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on, Heminapadisylat als Agonist des beta2-adrenergen Rezeptors

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE630296A (de) 1962-03-31
AT310146B (de) 1971-04-26 1973-09-25 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen
CH545764A (de) 1971-07-27 1974-02-15
BE794414A (fr) 1972-01-25 1973-07-23 Sandoz Sa Nouveaux amino-alcools, leur preparation et leur application comme medicament
FR2266497B1 (de) 1974-04-03 1977-11-04 Roussel Uclaf
JPS5913510B2 (ja) 1975-12-26 1984-03-30 オオツカセイヤク カブシキガイシヤ カルボスチリルユウドウタイノセイゾウホウ
JPS5283619A (en) 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd Alpha-substituted aminomethyl benzyl alcohol derivative
JPS609713B2 (ja) 1976-10-08 1985-03-12 大塚製薬株式会社 カルボスチリル誘導体
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB8507942D0 (en) 1985-03-27 1985-05-01 Beecham Group Plc Compounds
DK9987A (da) 1986-01-11 1987-07-12 Beecham Group Plc Ethanolaminderivater
US5223614A (en) 1987-12-19 1993-06-29 Boehringer Ingelheim Gmbh New quaternary ammonium compounds, their preparation and use
US4894219A (en) 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
US5434304A (en) 1990-09-26 1995-07-18 Aktiebolaget Astra Process for preparing formoterol and related compounds
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
US6075040A (en) 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
GB9713819D0 (en) 1997-06-30 1997-09-03 Glaxo Group Ltd Method of reducing the systemic effects of compounds
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US20020143034A1 (en) 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
WO2001007026A2 (en) 1999-07-22 2001-02-01 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
CA2405745A1 (en) 2000-04-27 2001-11-08 Boehringer Ingelheim Pharma Kg New betamimetics having a long-lasting activity, processes for preparingthem and their use as medicaments
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
EP1341759B1 (de) 2000-11-10 2006-06-14 Eli Lilly And Company 3-substituierte oxindolderivate als beta-3-agonisten
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
PT1425001E (pt) 2001-09-14 2009-02-18 Glaxo Group Ltd Derivados de fenetanolamina para o tratamento de doenças respiratórias
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
JP2005523920A (ja) 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド フェネタノールアミン誘導体
JP2005527618A (ja) 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
PL375195A1 (en) 2002-06-27 2005-11-28 Astellas Pharma Inc. Aminoalcohol derivatives
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
TW200409746A (en) 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7317102B2 (en) 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
EP1622875B1 (de) 2003-05-08 2009-12-02 Theravance, Inc. Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists
US7556785B2 (en) * 2003-05-12 2009-07-07 United Phosphorus, Ltd. Apparatus and method for rapid and continuous generation of phosphine gas
TW200510277A (en) 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
CN1984876A (zh) 2004-06-03 2007-06-20 施万制药 二胺类β2肾上腺素能受体激动剂
EP1778638A1 (de) 2004-07-21 2007-05-02 Theravance, Inc. Adrenergische diaryl ether beta2-rezeptoragonisten
JP2008512470A (ja) 2004-09-10 2008-04-24 セラヴァンス， インコーポレーテッド アミジン置換アリールアニリン化合物

Also Published As

Publication number Publication date
US20100087410A1 (en) 2010-04-08
BRPI0506823A (pt) 2007-05-29
TW200531692A (en) 2005-10-01
CN1910137A (zh) 2007-02-07
KR20070000466A (ko) 2007-01-02
US7622467B2 (en) 2009-11-24
JP5041814B2 (ja) 2012-10-03
IL176549A0 (en) 2006-10-31
NO20063620L (no) 2006-10-06
ZA200605720B (en) 2008-09-25
US20120071654A1 (en) 2012-03-22
ATE504559T1 (de) 2011-04-15
JP2007518738A (ja) 2007-07-12
AR047098A1 (es) 2006-01-04
NZ548196A (en) 2009-08-28
RU2006129312A (ru) 2008-02-20
US7994165B2 (en) 2011-08-09
RU2370490C2 (ru) 2009-10-20
EP1706371B1 (de) 2011-04-06
WO2005070872A1 (en) 2005-08-04
US20050159448A1 (en) 2005-07-21
AU2005206510A1 (en) 2005-08-04
CA2551821A1 (en) 2005-08-04
MA28304A1 (fr) 2006-11-01
CN1910137B (zh) 2010-05-26
EP1706371A1 (de) 2006-10-04
ES2364450T3 (es) 2011-09-02

Similar Documents

Publication Publication Date Title
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
ATE451364T1 (de) Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
DK1735304T3 (da) Quinolinoncarboxamidforbindelser som 5-HT4-receptoragonister
ATE517883T1 (de) Imidazolderivate als funktionelle selektive agonisten des alpha2c-adrenorezeptors
DE602006019624D1 (de) Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
DE602007014374D1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
DE602006003628D1 (de) Purinderivate als a2a-rezeptoragonisten
ATE497953T1 (de) Thiazolderivate als modulatoren des cannabinoidrezeptors
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
NL2000241A1 (nl) Carboxamidederivaten als muscarine-receptorantagonisten.
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
DE602005015204D1 (de) Oxadiazolonderivate als ppar-delta-agonisten
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
DK1899324T3 (da) Benzimidazolcarboxamid-forbindelser som 5-HT4-receptoragonister
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
ATE459618T1 (de) 3-piperidinylisochroman-5-ole als dopaminagonisten
DE112005002826A5 (de) Ausgleichseinheit
ATE512137T1 (de) Benzoylpiperidinderivate als doppelmodulatoren des 5-ht2a- und des d3-rezeptors
DE602006005242D1 (de) Pyrazolopyridinderivate als inhibitoren der kinase 1 des beta-adrenergen rezeptors
DE602006008002D1 (de) Benzofuranylderivate als 5-ht6-rezeptorinhibitoren